| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30000395 | HIV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS30088262 | HIV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20005944 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20016589 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20016635 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20015859 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20016587 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20016586 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20016584 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
| TVIS20016588 | HPV | ENSG00000078900.16 | protein_coding | TP73 | No | No | 7161 | A0A0C4DFW9 O15350 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TP73 |
|---|---|
| DrugBank ID | DB01593 |
| Drug Name | Zinc |
| Target ID | BE0008994 |
| UniProt ID | O15350 |
| Regulation Type | cofactor |
| PubMed IDs | 17170001 |
| Citations | Lokshin M, Li Y, Gaiddon C, Prives C: p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res. 2007;35(1):340-52. Epub 2006 Dec 14. |
| Groups | Approved; Investigational |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Zn] |
| Pathways | Dihydropyrimidinase Deficiency; Rofecoxib Action Pathway; Losartan Action Pathway; AICA-Ribosiduria; Canavan Disease; Quinapril Action Pathway; Alkaptonuria; Eprosartan Action Pathway; gamma-Glutamyltransferase Deficiency; Pterine Biosynthesis; Sulindac Action Pathway; Rescinnamine Action Pathway; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); beta-Ureidopropionase Deficiency; Vitamin B6 Metabolism; Retinol Metabolism; Valsartan Action Pathway; Valdecoxib Action Pathway; Irbesartan Action Pathway; Adenosine Deaminase Deficiency; Hawkinsinuria; Methionine Metabolism; Ramipril Action Pathway; Benazepril Action Pathway; beta-Alanine Metabolism; Aspartate Metabolism; Diclofenac Action Pathway; Galactosemia |
| PharmGKB | PA451956 |
| ChEMBL | CHEMBL1201279 |
